Loading...
New

Viral Vectors and Plasmid DNA Manufacturing Market by Product (Plasmid DNA, Viral Vectors, and Non-Viral Vectors) and Application (Cancers, Inherited Disorders, Viral Infections and Others): Global Opportunity Analysis and Industry Forecast, 2019-2027

A02348
Pages: 188
Sep 2020 | 9242 Views
 
Author(s) : Sagar Mukhekar, Smita Nerkar , Onkar Sumant
Tables: 94
Charts: 37
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Viral Vectors And Plasmid Dna Manufacturing Market

Request Now !

The global viral vectors and plasmid DNA manufacturing market size was valued at $918.37 million in 2019, and is estimated to reach at $4,978.54 million by 2027, registering a CAGR of 24.9% from 2020 to 2027. 

Gene therapy involves repairing, repressing, or replacing dysfunctional genes that cause disease with the aim of re-establishing normal function. This therapy serves as a promising treatment option for genetic diseases such as muscular dystrophy and cystic fibrosis as well as certain inherited disorders, cancers, and viral infections. Viral vectors and plasmid DNA manufacturing commonly includes use of system biology and panomics to determine the cause of a patient's illness at the molecular level, followed by use of concentrated medications to address individual patient's illness. Moreover, viral vectors and plasmid DNA can reduce cost of treatment and help decrease repeated administration of medications.

Viral-Vectors-and-Plasmid-DNA-Manufacturing-Market-2020-2027

Get more information on this report : Request Sample Pages

 

Increase in preference of viral vectors in various treatments has led to advancements in these vectors and plasmids. Advantages of using viral vectors include low risk of chromosomal integration; limited infection to broad spectrum of cells; robustness, owing to process validations; and easy culture production; which fuel their adoption and boost growth of the market.

The COVID-19 outbreak that started from Wuhan city of China has now wide spread globally. Almost every nation is dealing with the outbreak. Most of the markets are dropping down as COVID-19 outbreak has negatively affected various healthcare related markets. This pandemic is expected to present growth opportunities for the viral vector and plasmid DNA manufacturing market in the future as several viral vectors, recombinant protein, live attenuated virus, and nucleic acid-based vaccines are in (pre)clinical development for treatment of the diseases. Viral vector vaccines consist of a recombinant virus (which is the viral vector), frequently attenuated to reduce its pathogenicity, in which genes encoding viral antigen(s) are cloned using recombinant DNA methods. Vector vaccines can either be replicating or non-replicating. The major advantage of these vector-based vaccines is that a single dose can be sufficient for protection. In addition, companies in the viral vector manufacturing market are increasing their production facilities. 

Growth of the global viral vector and plasmid DNA manufacturing market is driven by rise in funding for R&D activities pertaining to gene therapy, rise in prevalence of cancer, viral infection, & genetic disorders, and increase in awareness regarding gene therapy. However, high cost associated with gene therapies and risk of mutagenesis & other impediments in gene therapy restrain the viral vectors and plasmid DNA manufacturing market growth. The impact of driving factors is expected to surpass that of the restraints. Moreover, increase in demand for synthetic genes and untapped potential for emerging markets are expected to provide new opportunities for viral vectors and plasmid DNA manufacturing market players in the future.

The global viral vectors and plasmid DNA manufacturing market is segmented on the basis of product, application, and region. On the basis of product, it is divided into plasmid DNA, viral vectors, and non-viral vectors. By application, it is categorized into cancer, inherited disorders, viral infections, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Product segment review

By product, the viral vector topical segment accounted for the largest viral vectors and plasmid DNA manufacturing market share in 2019, and is expected to maintain its dominance during the forecast period, owing to the necessity and applicability of these products in different research interventions. However, the plasmid DNA segment is projected to grow with the highest CAGR from 2020 to 2027, owing to its higher replication rate and ability to stay independent as it does not combine with genetic material of host cells. In addition, it plays a vital role in gene therapy, owing to its ability to easily manipulate & replicate and effectively target defective cells in the body.

Viral Vectors and Plasmid DNA Manufacturing Market
By Product

Your browser does not support the canvas element.

Viral Vectors segment holds a dominant position in 2019 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Application segment review

On the basis of application, the cancer segment was the largest revenue generating segment in the market in 2019, owing to requirements for quality drugs and versatile therapies for treatment. However, the inherited disorders segment is anticipated to be the highest growing segment with the highest CAGR from 2020 to 2027, owing to rise in incidences of inherited disorders, which has led to increase in R&D activities for development of therapies and, in turn, has led to emergence of novel therapies that involve use of viral vectors and plasmid DNA.

Viral Vectors and Plasmid DNA Manufacturing Market
By Application

Your browser does not support the canvas element.

Cancer Segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

North America held the highest market share in 2019, owing to high prevalence rate of cancer and modern healthcare facilities. Adoption of experimental medicines and growth in awareness regarding gene therapy are expected to boost the North America market. Asia-Pacific is expected to grow at the highest CAGR during the forecast period, owing to rapid industrialization in the area, increase in disposable income, and surge in government initiatives to modernize healthcare infrastructure.

Viral Vectors and Plasmid DNA Manufacturing Market
By Region

2027
North America 
Europe
Asia-pacific
Lamea

Asia Pacific region would exhibit the highest CAGR of 30.6% during 2020-2027.

Get more information on this report : Request Sample Pages

Some of the key players operating in the viral vectors and plasmid DNA manufacturing market include Cognate BioServices, Inc., Catalent Pharma Solutions, Fujifilm Holdings Corporation, Johnson & Johnson, Sanofi Corporation, F. Hoffmann-LA Roche Ltd, 4D Molecular Therapeutics, Sirion Biotech GmbH, Voyager therapeutics, and Thermo Fisher Scientific, Inc. Other players in the value chain analysis include, Cell and Gene Therapy Catapult, UniQure and MassBiologics, Renova Therapeutics, and Shenzhen SiBiono GeneTech Co., Ltd.

Key Benefits For Stakeholders

  • This report provides a detailed quantitative analysis of the current viral vectors and plasmid DNA manufacturing market trends and future estimations from 2020 to 2027, which assists in identifying prevailing viral vectors and plasmid DNA manufacturing market opportunities. 
  • An in-depth analysis of various regions is likely to provide a detailed understanding of the current trends to the stakeholders to formulate region-specific plans.
  • Comprehensive analysis of factors that drive and restrain growth of the viral vectors and plasmid DNA manufacturing market are provided.
  • Key regulatory guidelines for the viral vectors and plasmid DNA manufacturing market are critically dealt according to region.
  • A deep dive analysis of various regions provides insights that would allow companies to strategically plan their business moves.

Key Market Segments

By Product 

  • Plasmid DNA
  • Viral Vectors
  • Non-viral Vectors

By Application 

  • Cancers
  • Inherited Disorders
  • Viral Infections
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Australia
    • Japan
    • India
    • China
    • South Korea
    • Taiwan
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.2.3.Top player positioning, 2019

3.3.Porter’s five force analysis
3.4.Market dynamics

3.4.1.Drivers

3.4.1.1.Increase in funding for R&D activities pertaining to gene therapy
3.4.1.2.Rise in prevalence of cancer, viral infections, and genetic disorders
3.4.1.3.Increase in awareness regarding gene therapies

3.4.2.Restraints

3.4.2.1.High cost associated with gene therapies
3.4.2.2.Risk of mutagenesis and other impediments in gene therapy

3.4.3.Opportunities

3.4.3.1.Increase in demand for synthetic genes
3.4.3.2.Untapped markets in developing economies

3.5.COVID-19 Impact Analysis for Viral Vector and Plasmid DNA Manufacturing Market

CHAPTER 4:VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT

4.1.Overview

4.1.1.Market size and forecast

4.2.Viral vectors

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Plasmid DNA

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.Non-viral vectors

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

CHAPTER 5:VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Cancer

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Inherited disorder

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Viral Infection

5.4.1.Market opportunities associated with COVID 19 Pandemic
5.4.2.Market size and forecast, by region
5.4.3.Market analysis, by country

5.5.Others

5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country

CHAPTER 6:VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY REGION

6.1.Overview

6.1.1.Market size and forecast

6.2.North America

6.2.1.Key market trends, growth factors, and opportunities
6.2.2.North America viral vectors and plasmid DNA manufacturing market , by country

6.2.2.1.U.S. viral vectors and plasmid DNA manufacturing market, by product
6.2.2.2.U.S. viral vectors and plasmid DNA manufacturing market, by application
6.2.2.3.Canada viral vectors and plasmid DNA manufacturing market, by product
6.2.2.4.Canada viral vectors and plasmid DNA manufacturing market, by application
6.2.2.5.Mexico viral vectors and plasmid DNA manufacturing market, by product
6.2.2.6.Mexico viral vectors and plasmid DNA manufacturing market, by application

6.2.3.North America viral vectors and plasmid DNA manufacturing, by product
6.2.4.North America viral vectors and plasmid DNA manufacturing, by application

6.3.Europe

6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Europe viral vectors and plasmid DNA manufacturing, by country

6.3.2.1.UK viral vectors and plasmid DNA manufacturing market, by product
6.3.2.2.UK viral vectors and plasmid DNA manufacturing market, by application
6.3.2.3.Germany viral vectors and plasmid DNA manufacturing market, by product
6.3.2.4.Germany viral vectors and plasmid DNA manufacturing market, by application
6.3.2.5.France viral vectors and plasmid DNA manufacturing market, by product
6.3.2.6.France viral vectors and plasmid DNA manufacturing market, by application
6.3.2.7.Italy viral vectors and plasmid DNA manufacturing market, by product
6.3.2.8.Italy viral vectors and plasmid DNA manufacturing market, by application
6.3.2.9.Spain viral vectors and plasmid DNA manufacturing market, by product
6.3.2.10.Spain viral vectors and plasmid DNA manufacturing market, by application
6.3.2.11.Rest of Europe viral vectors and plasmid DNA manufacturing market, by product
6.3.2.12.Rest of Europe viral vectors and plasmid DNA manufacturing market, by application

6.3.3.Europe viral vectors and plasmid DNA manufacturing, by product
6.3.4.Europe viral vectors and plasmid DNA manufacturing, by application

6.4.Asia Pacific

6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Asia-Pacific viral vectors and plasmid DNA manufacturing market, by country

6.4.2.1.Japan viral vectors and plasmid DNA manufacturing market, by product
6.4.2.2.Japan viral vectors and plasmid DNA manufacturing market, by application
6.4.2.3.China viral vectors and plasmid DNA manufacturing market, by product
6.4.2.4.China viral vectors and plasmid DNA manufacturing market, by application
6.4.2.5.Australia viral vectors and plasmid DNA manufacturing market, by product
6.4.2.6.Australia viral vectors and plasmid DNA manufacturing market, by application
6.4.2.7.India viral vectors and plasmid DNA manufacturing market, by product
6.4.2.8.India viral vectors and plasmid DNA manufacturing market, by application
6.4.2.9.South Korea viral vectors and plasmid DNA manufacturing market, by product
6.4.2.10.South Korea viral vectors and plasmid DNA manufacturing market, by application
6.4.2.11.Taiwan viral vectors and plasmid DNA manufacturing market, by product
6.4.2.12.Taiwan viral vectors and plasmid DNA manufacturing market, by application
6.4.2.13.Rest of Asia-Pacific viral vectors and plasmid DNA manufacturing market, by product
6.4.2.14.Rest of Asia-Pacific viral vectors and plasmid DNA manufacturing market, by application

6.4.3.Asia-Pacific viral vectors and plasmid DNA manufacturing market, by product
6.4.4.Asia-Pacific viral vectors and plasmid DNA manufacturing market, by application

6.5.LAMEA

6.5.1.Key market trends, growth factors, and opportunities
6.5.2.LAMEA viral vectors and plasmid DNA manufacturing market, by country

6.5.2.1.Brazil viral vectors and plasmid DNA manufacturing market, by product
6.5.2.2.Brazil viral vectors and plasmid DNA manufacturing market, by application
6.5.2.3.Saudi Arabia viral vectors and plasmid DNA manufacturing market, by product
6.5.2.4.Saudi Arabia viral vectors and plasmid DNA manufacturing market, by application
6.5.2.5.South Africa viral vectors and plasmid DNA manufacturing market, by product
6.5.2.6.South Africa viral vectors and plasmid DNA manufacturing market, by application
6.5.2.7.Rest of LAMEA viral vectors and plasmid DNA manufacturing market, by product
6.5.2.8.Rest of LAMEA viral vectors and plasmid DNA manufacturing market, by application

6.5.3.LAMEA viral vectors and plasmid DNA manufacturing market, by product
6.5.4.LAMEA viral vectors and plasmid DNA manufacturing market, by application

CHAPTER 7:COMPANY PROFILES

7.1.COGNATE BIOSERVICES, INC.

7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segment
7.1.4.Product portfolio
7.1.5.Key strategic moves and developments

7.2.CATALENT PHARMA SOLUTIONS

7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segment
7.2.4.Product portfolio
7.2.5.Business performance
7.2.6.Key strategic moves and developments

7.3.FUJIFILM HOLDINGS CORPORATION

7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segment
7.3.4.Product portfolio
7.3.5.Business performance
7.3.6.Key strategic moves and developments

7.4.JOHNSON & JOHNSON

7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segment
7.4.4.Product portfolio
7.4.5.Business performance
7.4.6.Key strategic moves and developments

7.5.F. HOFFMANN-LA ROCHE LTD.

7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segment
7.5.4.Product portfolio
7.5.5.Business performance
7.5.6.Key strategic moves and developments

7.6.4D MOLECULAR THERAPEUTICS

7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segment
7.6.4.Product portfolio
7.6.5.Key strategic moves and developments

7.7.SANOFI CORPORATION

7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segment
7.7.4.Product portfolio
7.7.5.Business performance

7.8.SIRION BIOTECH GmbH

7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segment
7.8.4.Product portfolio

7.9.THERMO FISHER SCIENTIFIC, INC.

7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segment
7.9.4.Product portfolio
7.9.5.Business performance
7.9.6.Key strategic moves and developments

7.10.VOYAGER THERAPEUTICS INC.

7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segment
7.10.4.Product portfolio
7.10.5.Business performance
7.10.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 02.VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VIRAL VECTORS, BY REGION, 2019–2027 ($MILLION)
TABLE 03.VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PLASMID DNAS, BY REGION, 2019–2027 ($MILLION)
TABLE 04.VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY NON-VIRAL VECTORS, BY REGION, 2019–2027 ($MILLION)
TABLE 05.VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 06.VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY CANCER, BY REGION, 2019–2027 ($MILLION)
TABLE 07.VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY INHERITED DISORDERS, BY REGION, 2019–2027 ($MILLION)
TABLE 08.VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VIRAL INFECTION, BY REGION, 2019–2027 ($MILLION)
TABLE 09.VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY OTHERS, BY REGION, 2019–2027 ($MILLION)
TABLE 10.GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET REVENUE, BY REGION, 2019–2027 ($MILLION)
TABLE 11.NORTH AMERICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 12.U.S. VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 13.U.S. VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 14.CANADA VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 15.CANADA VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 16.MEXICO VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 17.MEXICO VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 18.NORTH AMERICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 19.NORTH AMERICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 20.EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 21.UK VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 22.UK VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 23.GERMANY VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 24.GERMANY VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 25.FRANCE VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 26.FRANCE VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 27.ITALY VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 28.ITALY VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 29.SPAIN VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 30.SPAIN VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 31.REST OF EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 32.REST OF EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 33.EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 34.EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 35.ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 36.JAPAN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT,  2019–2027 ($MILLION)
TABLE 37.JAPAN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION,  2019–2027 ($MILLION)
TABLE 38.CHINA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 39.CHINA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 40.AUSTRALIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 41.AUSTRALIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 42.INDIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 43.INDIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 44.SOUTH KOREA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 45.SOUTH KOREA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 46.TAIWAN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 47.TAIWAN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 48.REST OF ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 49.REST OF ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 50.ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 51.ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 52.LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 53.BRAZIL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 54.BRAZIL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 55.SAUDI ARABIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 56.SAUDI ARABIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 57.SOUTH AFRICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 58.SOUTH AFRICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 59.REST OF LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 60.REST OF LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 61.LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 62.LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 63.COGNATE: COMPANY SNAPSHOT
TABLE 64.COGNATE: OERATING SEGMENT
TABLE 65.COGNATE: PRODUCT PORTFOLIO
TABLE 66.COGNATE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 67.CATALENT: COMPANY SNAPSHOT
TABLE 68.CATALENT: OPERATING SEGMENTS
TABLE 69.CATALENT: PRODUCT PORTFOLIO
TABLE 70.CATALENT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 71.FUJIFILM: COMPANY SNAPSHOT
TABLE 72.FUJIFILM: OPERATING BUSINESS SEGMENT
TABLE 73.FUJIFILM: PRODUCT PORTFOLIO
TABLE 74.J&J: COMPANY SNAPSHOT
TABLE 75.J&J: OPERATING BUSINESS SEGMENT
TABLE 76.J&J: PRODUCT PORTFOLIO
TABLE 77.ROCHE: COMPANY SNAPSHOT
TABLE 78.ROCHE: OPERATING SEGMENTS
TABLE 79.ROCHE: PRODUCT PORTFOLIO
TABLE 80.4D: COMPANY SNAPSHOT
TABLE 81.4D: OPERATING SEGMENTS
TABLE 82.4D: PRODUCT PORTFOLIO
TABLE 83.SANOFI: COMPANY SNAPSHOT
TABLE 84.SANOFI: OPERATING SEGMENTS
TABLE 85.SANOFI: PRODUCT PORTFOLIO
TABLE 86.SIRION: COMPANY SNAPSHOT
TABLE 87.SIRION: OPERATING SEGMENTS
TABLE 88.SIRION: PRODUCT PORTFOLIO
TABLE 89.THERMO FISHER SCIENTIFIC.: COMPANY SNAPSHOT
TABLE 90.THERMO FISHER SCIENTIFIC: PRODUCT SEGMENT
TABLE 91.THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 92.VOYAGER: COMPANY SNAPSHOT
TABLE 93.VOYAGER: PRODUCT PORTFOLIO
TABLE 94.VOYAGER: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 01.VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, 2017–2020
FIGURE 04.TOP WINNING STRATEGIES: NATURE AND TYPE, 2017–2020
FIGURE 05.TOP WINNING STRATEGIES: BY YEAR, 2017–2020
FIGURE 06.TOP PLAYER POSITIONING, 2019
FIGURE 07.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 08.HIGH BARGAINING POWER OF BUYERS
FIGURE 09.HIGH THREAT OF SUBSTITUTES
FIGURE 10.MODERATE THREAT OF NEW ENTRANTS
FIGURE 11.MODERATE COMPETITIVE OF RIVALRY
FIGURE 12.DRIVER, RESTRAINSTS AND OPPORTUNITIES
FIGURE 13.COMPARATIVE ANALYSIS OF VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VIRAL VECTORS, BY REGION, 2019–2027 ($MILLION)
FIGURE 14.COMPARATIVE ANALYSIS OF VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PLASMID DNAS, BY REGION, 2019–2027 ($MILLION)
FIGURE 15.COMPARATIVE ANALYSIS OF VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY NON-VIRAL VECTORS, BY REGION, 2019–2027 ($MILLION)
FIGURE 16.COMPARATIVE ANALYSIS OF VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY CANCERS, BY REGION, 2019–2027 ($MILLION)
FIGURE 17.COMPARATIVE ANALYSIS OF VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY INHERITED DISORDERS, BY REGION, 2019–2027 ($MILLION)
FIGURE 18.COMPARATIVE ANALYSIS OF VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VIRAL INFECTION, BY REGION, 2019–2027 ($MILLION)
FIGURE 19.COMPARATIVE ANALYSIS OF VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY OTHERS, BY REGION, 2019–2027 ($MILLION)
FIGURE 20.CATALENT: NET SALES, 2017–2019 ($MILLION)
FIGURE 21.CATALENT: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 22.CATALENT: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 23.FUJIFILM: NET SALES, 2017–2019 ($MILLION)
FIGURE 24.FUJIFILM: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 25.J&J: NET SALES, 2017–2019 ($MILLION)
FIGURE 26.J&J: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 27.J&J: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 28.ROCHE: NET SALES, 2017–2019 ($MILLION)
FIGURE 29.ROCHE: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 30.ROCHE: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 31.SANOFI: NET SALES, 2017–2019 ($MILLION)
FIGURE 32.SANOFI: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 33.SANOFI: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 34.THERMO FISHER SCIENTIFIC, INC.: NET SALES, 2017–2019 ($MILLION)
FIGURE 35.THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 36.THERMO FISHER SCIENTIFIC. REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 37.VOYAGER: NET SALES, 2017–2019 ($MILLION)

 
 

This section provides opinions of top-level CXOs in the biotech & pharmaceutical industry. According to them, gene therapy is an innovative therapeutic approach that involves delivery of nucleic acid polymers into cells of patients for treating a disease. This procedure has various advantages, which include reduced number of drug administrations and concentrated therapeutic action. 

CXOs further stated that technological advancements in genetic research have led to increase in use of gene therapies to efficiently treat cancer and various diseases. Enhanced progression of gene therapies can be attributed to the growth and integration of cognitive computing and data analytics with healthcare. Moreover, increase in funding for R&D activities pertaining to gene therapy; rise in prevalence of cancer, viral infection, & genetic disorders; and increase in awareness regarding gene therapy are the major factors that boost the market growth.

According to CXOs, gene therapies are prominently used for cancer treatment, however in the future, they would be preferred for treatment of rare illnesses and conditions or disorders linked to aging.

 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library,  T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
 

A. The total market value of Viral Vectors and Plasmid DNA Manufacturing Market is $4,978.54 million in 2019.

A. The forcast period for Viral Vectors and Plasmid DNA Manufacturing Market is 2020 to 2027

A. The market value of Viral Vectors and Plasmid DNA Manufacturing Market in 2020 is $1,049.69 million.

A. The base year is 2019 in Viral Vectors and Plasmid DNA Manufacturing Market

A. Top companies such as, Cognate BioServices, Inc., Catalent Pharma Solutions, Fujifilm Holdings Corporation, Johnson & Johnson, Sanofi Corporation, F. Hoffmann-LA Roche Ltd, 4D Molecular Therapeutics, Sirion Biotech GmbH, Voyager therapeutics, and Thermo Fisher Scientific,.

A. Cancer segment is the most influencing segment owing to rise in requirement for quality drugs and versatile therapies for treatment are expected to boost growth of this segment

A. The major factor that fuels the growth of the Viral Vectors and Plasmid DNA Manufacturing Market includes Surge in global incidences of cancer and increase in ageing population susceptible to diseases are expected to boost the demand for viral vectors and plasmid DNA manufacturing.

A. No, there is no value chain analysis provided in the Viral Vectors and Plasmid DNA Manufacturing Market report

A. Viral vectors are tools commonly used by molecular biologists to deliver genetic material into cells. This process can be performed inside a living organism (in vivo) or in cell culture (in vitro).

A. Yes, Viral Vectors and Plasmid DNA Manufacturing companies are profiled in the report.

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Viral Vectors and Plasmid DNA Manufacturing Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library.  T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts